October 03, 2018
Altimmune Closes on $16.9 Million in Funding
Media
October 02, 2018
Nordic Nanovector: Abstracts of LYMRIT 37-01 Study with Betalutin® in NHL Patients and other Studies accepted for poster presentations at ASH
October 01, 2018
Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting
October 01, 2018
Orexo internalizes contract field force in the US to further strengthen the commercial organization
September 28, 2018
Altimmune Announces Pricing of $12 Million Underwritten Public Offering
September 27, 2018
Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018
September 27, 2018
Targovax announces interim results from Phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma
September 26, 2018
Vicore Pharma postpones publication of interim report
September 24, 2018
Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
September 24, 2018
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development